Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89Bio Inc (NQ: ETNB )

16.30 -0.64 (-3.78%)
Streaming Delayed Price Updated: 12:16 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,742,765
Open 17.30
Bid (Size) 16.30 (6)
Ask (Size) 16.33 (5)
Prev. Close 16.94
Today's Range 15.75 - 18.03
52wk Range 2.000 - 17.57
Shares Outstanding 52,230,621
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Why Shares of 89bio Soared This Week
The company released positive results for its lead therapy. 
Via The Motley Fool
89bio, Inc. Announces Upsized Pricing of $275 Million Public Offering of Common Stock
From 89bio, Inc.
Via Globe NewsWire

Performance

YTD
+36.17%
+36.17%
1 Month
+17.35%
+17.35%
3 Month
+41.13%
+41.13%
6 Month
+204.10%
+204.10%
1 Year
+313.71%
+313.71%

More News

Read More
KB Home, Accenture, Netflix And Other Big Stocks Moving Higher On Thursday
Via Benzinga
89Bio Inc. (NASDAQ: ETNB) Near the Top of Equities by Percentage Gain on 3/22
Via Investor Brand Network
Analyst Ratings for 89bio
Via Benzinga
Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
89bio To Rally 265%? Here Are 10 Other Analyst Forecasts For Thursday
Via Benzinga
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From 89bio, Inc.
Via Globe NewsWire
Dow Rises 75 Points; Fed Increases Rates By 25bps
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why 89bio Shares Are Trading Higher Today
Via Benzinga
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Nasdaq Edges Higher; Crude Oil Rises 1%
Via Benzinga
89bio (NASDAQ: ETNB) Reports Phase 2b ENLIVEN Trial of Pegozafermin Achieved Primary Endpoints For Treatment of Nonalcoholic Steatohepatitis (NASH)
Via Spotlight Growth
Exposures Product Safety
Why Are Meme Stocks GME, AMC, BBBY Up Today?
Via InvestorPlace
Travelzoo, Semler Scientific, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
SSYS Stock Alert: Stratasys Rejects Nano Dimension’s Takeover Offer
Via InvestorPlace
US Stocks Edge Lower Ahead Of Fed Decision; Nike Earnings Top Estimates
Via Benzinga
LAZR Stock Price Predictions: Why This Analyst Says Luminar Is Worth Just $5
Via InvestorPlace
Why Is 89bio (ETNB) Stock Up 34% Today?
Via InvestorPlace
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
From 89bio, Inc.
Via Globe NewsWire
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
Via Benzinga
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.